Authors: Sebastian Wolf
Publish Date: 2008/11/01
Volume: 52, Issue: 6, Pages: 433-439
Abstract
Vascular endothelial growth factor VEGF is an important modulator of angiogenesis and has been implicated in the pathology of a number of conditions including agerelated macular degeneration AMD diabetic retinopathy and cancer AMD is a progressive disease of the macula and the third major cause of blindness worldwide If not treated appropriately AMD can progress rapidly causing legal blindness within months of the second eye becoming affected Until recently the treatment options for AMD have been limited with photodynamic therapy PDT the mainstay treatment Although PDT is effective at slowing disease progression it rarely results in improved vision Pegaptanib and ranibizumab are both antiVEGF therapies licensed for the treatment of neovascular AMD in Europe however these drugs are not yet available in Japan This article reviews the available clinical data on antiVEGF therapies for the treatment of neovascular AMD in Europe and considers the future of this exciting therapy
Keywords: